Relevance of CYP3A5 Expression on the Clinical Outcome of Patients With Renal Cell Carcinoma

被引:2
|
作者
Matsumoto, Jun [1 ]
Kotera, Yumi [1 ]
Watari, Shogo [2 ]
Takeuchi, Koichi [1 ]
Ueki, Hideo [2 ]
Koyama, Toshihiro [3 ]
Wada, Koichiro [2 ]
Fujiyoshi, Masachika [1 ]
Nasu, Yasutomo [2 ]
Ariyoshi, Noritaka [1 ]
机构
[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Personalized Med & Prevent Healthcare Sci, Okayama, Japan
[2] Okayama Univ, Grad Sch Med Dent Pharmaceut Sci, Dept Urol, Okayama, Japan
[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pharmaceut Biomed, Okayama, Japan
关键词
human; cytochrome P450 CYP3A; renal cell carcinoma treatment outcome; CYTOCHROME-P450; 3A; OVARIAN-CANCER; IDENTIFICATION; RESISTANCE; ISOFORM; LIVER; RAT;
D O I
10.21873/anticanres.15029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: This study aimed to elucidate the detailed characteristics of CYP3A5 expression and the association between CYP3A5 expression and clinical outcomes in patients with renal cell carcinoma (RCC). Patients and Methods: This study retrospectively enrolled 124 Japanese patients with RCC treated at the Okayama University Hospital. The commonest CYP3A5 gene polymorphism, CYP3A5*3, and expression levels of CYP3A5 mRNA and protein in each tissue were examined. Results: Expression of CYP3A5 mRNA and protein in RCC tissues was significantly down-regulated compared to that in adjacent normal tissues. High level of CYP3A5 mRNA expression significantly extended cancer-specific survival (p=0.004) and overall survival (p=0.002). The CYP3A5 mRNA expression level was identified as a significant independent prognostic factor for both cancer-specific survival and overall survival. Conclusion: CYP3A5 could serve as a potential marker for prognostication and treatment planning for patients with RCC.
引用
收藏
页码:2511 / 2521
页数:11
相关论文
共 50 条
  • [11] Statin regulation of CYP3A4 and CYP3A5 expression
    Vieira Willrich, Maria Alice
    Hirata, Mario Hiroyuki
    Crespo Hirata, Rosario Dominguez
    PHARMACOGENOMICS, 2009, 10 (06) : 1017 - 1024
  • [12] Effect of CYP3A5 genotype on the relationship between hepatic CYP3A activity and CYP3A4 and CYP3A5 mRNA expression
    Kolwankar, D
    Ho, H
    Ethell, B
    Vuppalanchi, R
    Marri, SR
    Wrighton, SA
    Jones, DR
    Hall, SD
    DRUG METABOLISM REVIEWS, 2004, 36 : 118 - 118
  • [13] Donor CYP3A5 Expression Decreases Renal Transplantation Outcomes in White Renal Transplant Recipients
    Warzyszynska, Karola
    Zawistowski, Michal
    Karpeta, Edyta
    Jalbrzykowska, Agnieszka
    Kosieradzki, Maciej
    ANNALS OF TRANSPLANTATION, 2022, 27
  • [14] The population pharmacokinetics of sirolimus and CYP3A5*3 polymorphism in Chinese renal transplant patients
    Shi, Hao-Qiang
    Yang, Jun
    Zhang, Li-Qun
    Xu, Bei-Ming
    Lu, Hui-Lan
    Chen, Er-Zhen
    Chen, Bing
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (03): : 5854 - 5866
  • [15] CYP3A5*3 Genetic Polymorphism and Tacrolimus Concentration in Myanmar Renal Transplant Patients
    Htun, Y. Y.
    Swe, H. K.
    Saw, T. M.
    TRANSPLANTATION PROCEEDINGS, 2018, 50 (04) : 1034 - 1040
  • [16] Analysis of CYP3A5*3 and CYP3A5*6 Gene Polymorphisms in Indian Chronic Myeloid Leukemia Patients
    Sailaja, K.
    Surekha, D.
    Rao, D. Nageswara
    Rao, D. Raghunadha
    Vishnupriya, S.
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2010, 11 (03) : 781 - 784
  • [17] Influence of CYP3A5 polymorphism on tacrolimus blood concentrations in renal transplant patients
    Nie, XM
    Gui, R
    Zhao, HS
    Ma, DL
    Li, DQ
    Yuan, H
    Huang, ZF
    JOURNAL OF CENTRAL SOUTH UNIVERSITY OF TECHNOLOGY, 2005, 12 (Suppl 1): : 310 - 312
  • [18] Influence of CYP3A5 polymorphism on tacrolimus blood concentrations in renal transplant patients
    Xin-min Nie
    Rong Gui
    Hong-shan Zhao
    Da-long Ma
    Deng-qing Li
    Hong Yuan
    Zu-fa Huang
    Journal of Central South University of Technology, 2005, 12 : 310 - 312
  • [19] Association Between CYP3A5☆1 and CYP3A5☆3 Polymorphisms, With the Formation of ADES and the Presence of Rejection in Renal Transplant Recipients
    Garcia, Luis
    Quintanilla, Alan
    Hinojosa, Hector
    Vargas, Lionel
    Fernandez, Diana
    Garcia, Aldo
    TRANSPLANTATION, 2022, 106 (09) : S275 - S275
  • [20] Tacrolimus Dose Requirement Based on the CYP3A5 Genotype in Renal Transplant Patients
    Qu, L.
    Xie, Z.
    Huang, H.
    Jiang, H.
    Chen, J.
    Jiang, H.
    Jiang, H.
    Chen, J.
    Chen, J.
    Chen, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 747 - 747